tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Australian Clinical Labs Ltd Issues New Equity Securities

Story Highlights
Australian Clinical Labs Ltd Issues New Equity Securities

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an announcement.

Australian Clinical Labs Ltd announced the issuance and conversion of unquoted equity securities, specifically 15,662 ordinary fully paid shares. This move is part of the company’s ongoing financial management and could impact its capital structure, potentially influencing its market positioning and stakeholder interests.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

More about Australian Clinical Labs Ltd

Australian Clinical Labs Ltd operates in the healthcare industry, providing pathology services and diagnostic testing. The company focuses on delivering high-quality medical testing services across Australia, catering to both public and private healthcare sectors.

Average Trading Volume: 927,021

Technical Sentiment Signal: Sell

Current Market Cap: A$536.1M

See more insights into ACL stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1